Matches in SemOpenAlex for { <https://semopenalex.org/work/W2775348523> ?p ?o ?g. }
- W2775348523 endingPage "125" @default.
- W2775348523 startingPage "117" @default.
- W2775348523 abstract "Introduction: Type 2 diabetes mellitus has become a growing epidemic and therefore efficient treatment strategies that target its management are needed. The treatment of diabetic patients often requires the combination of antidiabetic drug classes. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) block glucose reabsorption in the proximal renal tubules. Dipeptidyl peptidase-4 inhibitors (DPP-4i) improve glucose metabolism by blocking the enzyme that degrades incretins leading to increased insulin secretion.Areas covered: The aim of the review is to present the available data on pharmacokinetic properties/pharmacodynamics, metabolic and cardiovascular effects of empagliflozin plus linagliptin combination.Expert opinion: Both empagliflozin and linagliptin have established safety and efficacy in the treatment of diabetes. Available data demonstrate the absence of pharmacological interactions when the two drugs are given together. The complementary mechanisms of action would be expected to provide additive benefits on carbohydrate metabolism variables, but the results from clinical trials have shown that the empagliflozin/linagliptin combination provides only mild improvements of glycated hemoglobin compared with either monotherapy. However, the single-tablet formulation of empagliflozin/linagliptin is expected to provide better compliance and thus improved glycaemic control coupled with a favourable safety profile. Thus, the fixed-dose combination of empagliflozin/linagliptin has the capacity to both effectively and safely manage diabetic patients." @default.
- W2775348523 created "2017-12-22" @default.
- W2775348523 creator A5032218366 @default.
- W2775348523 creator A5056379080 @default.
- W2775348523 creator A5078585608 @default.
- W2775348523 date "2017-12-19" @default.
- W2775348523 modified "2023-09-24" @default.
- W2775348523 title "Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes" @default.
- W2775348523 cites W1209385844 @default.
- W2775348523 cites W1497388823 @default.
- W2775348523 cites W1682854201 @default.
- W2775348523 cites W1714643869 @default.
- W2775348523 cites W1770274352 @default.
- W2775348523 cites W1893948433 @default.
- W2775348523 cites W1955935325 @default.
- W2775348523 cites W1972948968 @default.
- W2775348523 cites W1982856763 @default.
- W2775348523 cites W1988728194 @default.
- W2775348523 cites W1993014774 @default.
- W2775348523 cites W1994521895 @default.
- W2775348523 cites W1997490166 @default.
- W2775348523 cites W2001209027 @default.
- W2775348523 cites W2006925617 @default.
- W2775348523 cites W2007293458 @default.
- W2775348523 cites W2010055261 @default.
- W2775348523 cites W2021517048 @default.
- W2775348523 cites W2031484324 @default.
- W2775348523 cites W2037843621 @default.
- W2775348523 cites W2038051506 @default.
- W2775348523 cites W2040580117 @default.
- W2775348523 cites W2057679405 @default.
- W2775348523 cites W2064130493 @default.
- W2775348523 cites W2067579363 @default.
- W2775348523 cites W2069662979 @default.
- W2775348523 cites W2076450470 @default.
- W2775348523 cites W2088113192 @default.
- W2775348523 cites W2098292453 @default.
- W2775348523 cites W2101344933 @default.
- W2775348523 cites W2111069331 @default.
- W2775348523 cites W2112417193 @default.
- W2775348523 cites W2114493476 @default.
- W2775348523 cites W2115951150 @default.
- W2775348523 cites W2117402345 @default.
- W2775348523 cites W2118619033 @default.
- W2775348523 cites W2119981294 @default.
- W2775348523 cites W2127854619 @default.
- W2775348523 cites W2134652590 @default.
- W2775348523 cites W2137069992 @default.
- W2775348523 cites W2142830692 @default.
- W2775348523 cites W2144325462 @default.
- W2775348523 cites W2146264128 @default.
- W2775348523 cites W2147743786 @default.
- W2775348523 cites W2153839551 @default.
- W2775348523 cites W2155873662 @default.
- W2775348523 cites W2157405334 @default.
- W2775348523 cites W2157606430 @default.
- W2775348523 cites W2158136745 @default.
- W2775348523 cites W2158506982 @default.
- W2775348523 cites W2161852973 @default.
- W2775348523 cites W2166613497 @default.
- W2775348523 cites W2169274492 @default.
- W2775348523 cites W2171183320 @default.
- W2775348523 cites W2198388354 @default.
- W2775348523 cites W2273304042 @default.
- W2775348523 cites W2294512307 @default.
- W2775348523 cites W2387749804 @default.
- W2775348523 cites W2424539745 @default.
- W2775348523 cites W2442475309 @default.
- W2775348523 cites W2523321497 @default.
- W2775348523 cites W2530979034 @default.
- W2775348523 cites W2532067257 @default.
- W2775348523 cites W2537155629 @default.
- W2775348523 cites W2542514797 @default.
- W2775348523 cites W2547375753 @default.
- W2775348523 cites W2552168025 @default.
- W2775348523 cites W2552966671 @default.
- W2775348523 cites W2558145946 @default.
- W2775348523 cites W2571987386 @default.
- W2775348523 cites W2590820596 @default.
- W2775348523 cites W2591585197 @default.
- W2775348523 cites W2598251971 @default.
- W2775348523 cites W2606133792 @default.
- W2775348523 cites W2606655110 @default.
- W2775348523 cites W2618856448 @default.
- W2775348523 cites W2619772777 @default.
- W2775348523 cites W2620745393 @default.
- W2775348523 cites W2624032915 @default.
- W2775348523 cites W2653321410 @default.
- W2775348523 cites W2739456155 @default.
- W2775348523 cites W2741027917 @default.
- W2775348523 cites W2742940683 @default.
- W2775348523 cites W2765639474 @default.
- W2775348523 cites W2975430135 @default.
- W2775348523 cites W4214911496 @default.
- W2775348523 doi "https://doi.org/10.1080/17425255.2018.1418325" @default.
- W2775348523 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29241374" @default.
- W2775348523 hasPublicationYear "2017" @default.
- W2775348523 type Work @default.